Rhino-orbital-cerebral zygomycosis in solid organ transplant recipients

Transplantation

Volumn 90, Issue 1, 2010, Pages 85-92

  Sun, Hsin Yun ^a,b   Forrest, Graeme ^c   Gupta, Krishan L ^d   Aguado, Jose M ^e   Lortholary, Olivier ^f,g   Julia, Marino Blanes ^h   Safdar, Nasia ⁱ   Patel, Robin ^j   Kusne, Shimon ^k   Singh, Nina ^a,l  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^c UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^d POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

^e Unit of Infectious Diseases   (Spain)

^f UNIVERSITÉ PARIS DESCARTES   (France)

^g INSTITUT PASTEUR   (France)

^h HOSPITAL UNIVERSITARIO LA FE   (Spain)

ⁱ UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^j MAYO CLINIC   (United States)

^k MAYO CLINIC   (United States)

^l UNIVERSITY OF PITTSBURGH   (United States)

more..

Author keywords

Rhino orbital cerebral.; Solid organ transplant; Zygomycosis

Indexed keywords

AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX;

ADULT; AGE; AGED; ARTICLE; CENTRAL NERVOUS SYSTEM DISEASE; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; GRAFT RECIPIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; MUCORMYCOSIS; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; RHINOORBITAL CEREBRAL ZYGOMYCOSIS; RISK FACTOR; SURVIVAL; TREATMENT OUTCOME;

ADULT; AGED; AMPHOTERICIN B; ANTIFUNGAL AGENTS; BRAIN DISEASES; COHORT STUDIES; DEBRIDEMENT; FEMALE; HUMANS; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; MYCOSES; ORGAN TRANSPLANTATION; REGRESSION ANALYSIS; SINUSITIS; ZYGOMYCOSIS;

EID: 77954611098     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e3181dde8fc     Document Type: Article

References (83)

1. Kontoyiannis DP, Lionakis MS, Lewis RE, et al. Zygomycosis in a tertiary-care cancer center in the era of Aspergillus-active antifungal therapy: A case-control observational study of 27 recent cases. J Infect Dis 2005; 191: 1350.
2. Bitar D, Van Cauteren D, Lanternier F, et al. Increasing incidence of zygomycosis (mucormycosis), France, 1997-2006. Emerg Infect Dis 2009; 15: 1395.
3. Pappas PG, Kauffman CA, Alexander B, et al. Prospective surveillance of invasive fungal infections (IFIs) among organ transplant recipients (OTRs) in the U.S. 2001-2006: Review of TRANSNET [abstract M-1195]. Presented atthe 47th Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, 17-20 September, 2007.
4. Husain S, Alexander BD, Munoz P, et al. Opportunistic mycelial fungal infectionsinorgan transplant recipients: Emerging importance ofnon-Aspergillus mycelial fungi. Clin Infect Dis 2003; 37: 221.
5. Singh N, Aguado JM, Bonatti H, et al. Zygomycosis in solid organ transplant recipients: A prospective, matched case-control study to assess risks for disease and outcome. J Infect Dis 2009; 200: 1002.
6. Almyroudis NG, Sutton DA, Linden P, et al. Zygomycosis in solid organ transplant recipients in a tertiary transplant center and review of the literature. Am J Transplant 2006; 6: 2365.
7. Roden MM, Zaoutis TE, Buchanan WL, et al. Epidemiology and outcome of zygomycosis: A review of 929 reported cases. Clin Infect Dis 2005; 41: 634.
8. Lanternier F, Lortholary O. Zygomycosis and diabetes mellitus. Clin Microbiol Infect 2009; 15(suppl 5): 21.
9. Ascioglu S, Rex JH, de Pauw B, et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: An international consensus. Clin Infect Dis 2002; 34: 7.
10. Halloran PF. Immunosuppressive drugs for kidney transplantation. N Engl J Med 2004; 351: 2715.
11. Al Soub H, El Deeb Y, Almaslaman IM, et al. Zygomycosis in Qatar: A retrospective review of six cases. Eur Ann Allergy Clin Immunol 2004; 36: 387.
12. Altiparmak MR, Apaydin S, Trablus S, et al. Systemic fungal infections after renal transplantation. Scand J Infect Dis 2002; 34: 284.
13. Apaydin S, Ataman R, Cansiz H, et al. Rhinocerebral mucormycosis in a kidney transplant recipient. Nephron 1998; 79: 117.
14. AslaniJ, EizadiM, Kardavani B, et al. Mucormycosis after kidney transplantations: Report of seven cases. Scand J Infect Dis 2007; 39: 703.
15. Bakr A, Wafa E, Fouda A, et al. Successful treatment of mucormycosis in a renal allograft recipient. Clin Exp Nephrol 2008; 12: 207.
16. Blitzer A, Lawson W, Meyers BR, et al. Patient survival factors in para-nasal sinus mucormycosis. Laryngoscope 1980; 90: 635.
17. Braf ZF, Altmann G, Ostfeld E. Fungal infections after renal transplantation. Isr J Med Sci 1976; 12: 674.
18. Budreau JP, Straatman D, Mogridge C, et al. Rhinocerebral mucormy-cosis in a cyclosporine-treated renal transplant patient. Clin Transpl 1989: 305.
19. Carbone KM, Pennington LR, Gimenez LF, et al. Mucormycosis in renal transplant patients\A report of two cases and review of the literature. Q J Med 1985; 57: 825.
20. Chakrabarti A, Das A, Sharma A, et al. Ten years' experience in zygo-mycosis at a tertiary care centre in India. J Infect 2001; 42: 261.
21. Chitsaz S, Bagheri J, Mandegar MH, et al. Extensive sino-orbital zygo-mycosis after heart transplantation: A case report. Transplant Proc 2009; 41: 2927.
22. Chugh KS, Sakhuja V, Jain S, et al. High mortality in systemic fungal infections following renal transplantation in third-world countries. Nephrol Dial Transplant 1993; 8: 168.
23. Cohen SG, Greenberg MS. Rhinomaxillary mucormycosis in a kidney transplant patient. Oral Surg Oral Med Oral Pathol 1980; 50: 33.
24. Forrest GN, MankesK.Outcomesofinvasive zygomycosis infections in renal transplant recipients. Transpl Infect Dis 2007; 9: 161.
25. Haim S, Better OS, Lichtig C, et al. Rhinocerebral mucormycosis following kidney transplantation. Isr J Med Sci 1970; 6: 646.
26. Hammer GS, Bottone EJ, Hirschman SZ. Mucormycosisinatransplant recipient. Am J Clin Pathol 1975; 64: 389.
27. Henriquez M, Levy R, Raja RM, et al. Mucormycosis in a renal transplant recipient with successful outcome. JAMA 1979; 242: 1397.
28. Herbrecht R, Letscher-Bru V, Bowden RA, et al. Treatment of 21 cases of invasive mucormycosis with amphotericin B colloidal dispersion. Eur J Clin Microbiol Infect Dis 2001; 20: 460.
29. Hooper DC, Pruitt AA, Rubin RH. Central nervous system infection in the chronically immunosuppressed. Medicine (Baltimore) 1982; 61: 166.
30. Jimenez C, Lumbreras C, Aguado JM, et al. Successful treatment of Mucor infection after liver or pancreas-kidney transplantation. Transplantation 2002; 73: 476.
31. Kaplan AH, Poza-Juncal E, Shapiro R, et al. Cure of mucormycosis in a renal transplant patient receiving ciclosporin with maintenance of im-munosuppression. Am J Nephrol 1988; 8: 139.
32. Kolbeck PC, Makhoul RG, Bollinger RR, et al. Widely disseminated Cunninghamella mucormycosis in an adult renal transplant patient: Case report and review of the literature. Am J Clin Pathol 1985; 83: 747.
33. Kumar S, Trivedi HL, Smith EK. Letter: Rhinocerebral mucormycosis in a renal transplant patient. J Oral Surg 1976; 34: 583.
34. Ladurner R, Brandacher G, Steurer W, et al. Lessons to be learned from a complicated case of rhino-cerebral mucormycosis in a renal allograft recipient. Transpl Int 2003; 16: 885.
35. Marchevsky AM, Bottone EJ, Geller SA, et al. The changing spectrum of disease, etiology, and diagnosis of mucormycosis. Hum Pathol 1980; 11: 457.
36. Miladipour A, Ghanei E, Nasrollahi A, et al. Successful treatment of mu-cormycosis after kidney transplantation. Iran J Kidney Dis 2008; 2: 163.
37. Montgomery JR, Barrett FF, Williams TW Jr. Infectious complications in cardiac transplant patients. Transplant Proc 1973; 5: 1239.
38. Morduchowicz G, Shmueli D, Shapira Z, et al. Rhinocerebral mucor-mycosis in renal transplant recipients: Report of three cases and review of the literature. Rev Infect Dis 1986; 8: 441.
39. Munckhof W, Jones R, Tosolini FA, et al. Cure of Rhizopus sinusitis in a liver transplant recipient with liposomal amphotericin B. Clin Infect Dis 1993; 16: 183.
40. Narang AK, Dina TS. Cerebral mucormycosis: A case report. Comput Med Imaging Graph 1988; 12: 259.
41. Nimmo GR, Whiting RF, Strong RW. Disseminated mucormycosis due toCunninghamella bertholletiaeinaliver transplant recipient. Postgrad Med J 1988; 64: 82.
42. Peterson PK, Dahl MV, Howard RJ, et al. Mucormycosis and cutaneous histoplasmosis in a renal transplant recipient. Arch Dermatol 1982; 118: 275.
43. Peterson KL, Wang M, Canalis RF, et al. Rhinocerebral mucormycosis: Evolution of the disease and treatment options. Laryngoscope 1997; 107: 855.
44. Ramon Y, Oberman M, Horowitz I, et al. Extensive maxillary sequestration resulting from rhinocerebral mucormyocosis. J Oral Surg 1977; 35: 989.
45. Sakhuja V, Sud K, Kalra OP, et al. Central nervous system complications in renal transplant recipients in a tropical environment. J Neurol Sci 2001; 183: 89.
46. Schober R, Herman MM. Neuropathology of cardiac transplantation. Survey of 31 cases. Lancet 1973; 1: 962.
47. Spellberg B, AndesD, Perez M, et al. Safety and outcomes of open-label deferasirox iron chelation therapy for mucormycosis. Antimicrob Agents Chemother 2009; 53: 3122.
48. Stevens KM, Newell RC, Bergstrom L. Mucormycosis in a patient receiving azathioprine. Arch Otolaryngol 1972; 96: 250.
49. Stinson EB, Bieber CP, Griepp RB, et al. Infectious complications after cardiac transplantation in man. Ann Intern Med 1971; 74: 22.
50. Sundaram C, Mahadevan A, Laxmi V, et al. Cerebral zygomycosis. Mycoses 2005; 48: 396.
51. Thorsteinsson SB, Musher DM, Ortiz LR, et al. Phycomycosis inarenal transplant recipient. Tex Med 1976; 72: 71.
52. Varma PP, Hooda AK, Badwal S. Laryngeal stridor and myocardial infarction in a renal transplant recipient. Natl Med J India 2009; 22: 70.
53. Vetrone G, Grazi GL, Ercolani G, et al. Successful treatment of rhino-maxillary form ofmucormycosis infection after liver transplantation: A case report. Transplant Proc 2006; 38: 1445.
54. Webb M, Dowdy L, Bundschu C, et al. Cerebral mucormycosis after liver transplantation: A case report. Clin Transplant 1998; 12: 596.
55. Yassin MA, Taj-Aldeen SJ, Khan FY, et al. Rhino-orbital zygomycosis secondary to Rhizopus oryzae in a renal transplant recipient successfully treated with liposomal amphotericin B. Chang Gung Med J 2008; 31: 407.
56. Yohai RA, Bullock JD, Aziz AA, et al. Survival factors in rhino-orbital-cerebral mucormycosis. Surv Ophthalmol 1994; 39: 3.
57. Zhang R, Zhang JW, Szerlip HM. Endocarditis and hemorrhagic stroke caused by Cunninghamella bertholletiae infection after kidney transplantation. Am J Kidney Dis 2002; 40: 842.
58. Zwas ST, Czerniak P. Head and brain scan findings in rhinocerebral mucormycosis: Case report. J Nucl Med 1975; 16: 925.
59. Sehgal A, Raghavendran M, Kumar D, et al. Rhinocerebral mucormy-cosis causing basilar artery aneurysm with concomitant fungal colonic perforation in renal allograft recipient: A case report. Transplantation 2004; 78: 949.
60. Sohail MA, Al Khabori M, Hyder J, et al. Acute fulminant fungal sinusitis: Clinical presentation, radiological findings and treatment. Acta Trop 2001; 80: 177.
61. Ramos A, Cuervas-Mons V, Noblejas A, et al. Breakthrough rhinoce-rebral mucormycosis in a liver transplant patient receiving caspofun-gin. Transplant Proc 2009; 41: 1972.
62. Bhansali A, Bhadada S, Sharma A, et al. Presentation and outcome of rhino-orbital-cerebral mucormycosis in patients with diabetes. Postgrad Med J 2004; 80: 670.
63. Spellberg B, Walsh TJ, Kontoyiannis DP, et al. Recent advances in the management of mucormycosis: From bench to bedside. Clin Infect Dis 2009; 48: 1743.
64. Clemons KV, Sobel RA, Williams PL, et al. Efficacy of intravenous liposomal amphotericin B (AmBisome) against coccidioidal meningitis in rabbits. Antimicrob Agents Chemother 2002; 46: 2420.
65. Albert MM, Stahl-Carroll L, Luther MF, et al. Comparisonof liposomal amphotericin B to amphotericin B for treatment of murine cryptococ-cal meningitis. J Mycol Med 1995; 5: 1.
66. Takemoto K, Yamamoto Y, Ueda Y. Influence of the progression of cryptococcal meningitis on brain penetration and efficacy of AmBi-some in a murine model. Chemotherapy 2006; 52: 271.
67. Groll AH, Giri N, Petraitis V, et al. Comparative efficacy and distribution of lipid formulations of amphotericin B in experimental Candida albicans infection of the central nervous system. J Infect Dis 2000; 182: 274.
68. Ibrahim AS, Avanessian V, Spellberg B, et al. Liposomal amphotericin B, and not amphotericin B deoxycholate, improves survival of diabetic mice infected withRhizopus oryzae. Antimicrob Agents Chemother2003; 47: 3343.
69. Ibrahim AS, Gebremariam T, Husseiny MI, et al. Comparison of lipid amphotericin B preparations in treating murine zygomycosis. Antimi-crob Agents Chemother 2008; 52: 1573.
70. Pagano L, Girmenia C, Mele L, et al. Infections caused by filamentous fungi in patients with hematologic malignancies. A report of 391 cases by GIMEMA Infection Program. Haematologica 2001; 86: 862.
71. Pagano L, Offidani M, Fianchi L, et al. Mucormycosis in hematologic patients. Haematologica 2004; 89: 207.
72. Cordonnier C, Bresnik M, Ebrahimi R. Liposomal amphotericin B (AmBisome) efficacy in confirmed invasive aspergillosis and other filamentous fungal infections in immunocompromised hosts: A pooled analysis. Mycoses 2007; 50: 205.
73. Walsh TJ, Goodman JL, Pappas P, et al. Safety, tolerance, and pharma-cokinetics of high-dose liposomal amphotericin B (AmBisome) in patients infected with Aspergillus species and other filamentous fungi: Maximum tolerated dose study. Antimicrob Agents Chemother 2001; 45: 3487.
74. Ruping MJ, Heinz WJ, Kindo AJ, et al. Forty-one recent cases of invasive zygomycosis froma global clinical registry.J Antimicrob Chemother 2010; 65: 296.
75. Walsh TJ, Hiemenz JW, Seibel NL, et al. Amphotericin B lipid complex for invasive fungal infections: Analysis of safety and efficacy in 556 cases. Clin Infect Dis 1998; 26: 1383.
76. Larkin JA, Montero JA. Efficacy and safety of amphotericin B lipid complex for zygomycosis. Infect Med 2003; 20: 201.
77. Gleissner B, Schilling A, Anagnostopolous I, et al. Improved outcome of zygomycosis in patients with hematological diseases Leuk Lym-phoma 2004; 45: 1351.
78. Pagano L, Valentini CG, Posteraro B, et al. Zygomycosis in Italy: A survey of FIMUA-ECMM (Federazione Italiana di Micopatologia Umana ed Animale and European Confederation of Medical Mycology). J Chemother 2009; 21: 322.
79. Petrikkos GL. Lipid formulations of amphotericin B as first-line treatment of zygomycosis. Clin Microbiol Infect 2009; 15(suppl 5): 87.
80. Lamaris GA, Lewis RE, Chamilos G, et al. Caspofungin-mediated beta-glucan unmasking and enhancement of human polymorphonuclear neutrophil activity againstAspergillus and non-Aspergillus hyphae.J Infect Dis 2008; 198: 186.
81. Spellberg B, Fu Y, Edwards JE Jr, et al. Combination therapy with am-photericin B lipid complex and caspofungin acetate of disseminated zygomycosis in diabetic ketoacidotic mice. Antimicrob Agents Che-mother 2005; 49: 830.
82. Reed C, Bryant R, Ibrahim AS, et al. Combination polyene-caspofungin treatment of rhino-orbital-cerebral mucormycosis. Clin Infect Dis 2008; 47: 364.
83. Kontoyiannis DP, Lewis RE. Agents of mucormycosis and entomoph-thoramycosis. In: Mandell GL, Bennett JE, Dolin R, eds. Principles and practice of infectious diseases [ed. 7]. Philadelphia, PA, Churchill Liv-ingstone/Elsevier 2009.